Sinovac Biotech, a reputed name in the pharmaceutical Industry in China has placed on record the successful initial phase of the H5N1 bird flu vaccine . The vaccine is said to operate in low doses, nearly one-third to two-thirds lower than the dosage used in the trials undertaken till date. The smaller doses are proven to be more effective.
During the trials it was observed that just two 10-microgram doses of the Sinovac vaccine, in combination with alum, gave immunity to nearly 65% of the people, six weeks after the commencement of the clinical trails.
Advertisement
The Chinese results are extremely positive which means within six months of round the clock working by the manufacturing companies, sufficient vaccine will be produced to cater to 742 million people, which will help in tiding over a potential pandemic.
Source: Medindia
SAV
SAV
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Bird Flu News
Researchers monitored the continuing avian flu pandemic to gauge its evolving risk to both humans and birds.
Bird flu in Brazil: Authorities are watching if the bird flu virus H5N1 is mutating into a form which can spread amongst humans.
Bird flu outbreak: New mutation in avian influenza virus (H5N1) could be the next human pandemic, warn health experts.
Exposure to live or dead poultry contaminated with avian influenza A virus results in the increase of human cases of avian influenza infection.
In environments where avian influenza virus may be present, the WHO advises regular hand washing and good food safety and food hygiene practices.